Drug intelligence / Profile preview

anlotinib + bevacizumab + camrelizumab + pembrolizumab + sintilimab + tislelizumab

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

This combination involves multiple drugs with different mechanisms of action: - **Anlotinib**: A multi-target tyrosine kinase inhibitor targeting VEGFR, PDGFR, FGFR, and c-Kit, primarily used for its anti-angiogenic effects. - **Bevacizumab**: A monoclonal antibody targeting vascular endothelial growth factor (VEGF), used to inhibit angiogenesis. - **Camrelizumab, Pembrolizumab, Sintilimab, and Tislelizumab**: These are checkpoint inhibitors targeting PD-1, enhancing the immune response against cancer cells.

Targets

PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)ULBP2 (UL16-binding protein 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFA (Vascular endothelial growth factor A)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)

Beyond the preview

Go deeper on anlotinib + bevacizumab + camrelizumab + pembrolizumab + sintilimab + tislelizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anlotinib + bevacizumab + camrelizumab + pembrolizumab + sintilimab + tislelizumab.

Explore the full profile